A strategy involving the electroporation of anti-CD123-CAR mRNA into “biodegradable” T cells in patients with R/R AML (NCT02623582) was terminated due to an absence of an anti-tumor effect.303 Finally, a case report from a pivotal trial testing a fourth-generation, apoptosis-inducible lentiviral CAR targeting CD123 has been published,262 but there is no further evidence of this construct. The gene discussed is IL3RA; the disease is acute myeloid leukemia.